view4D pharma PLC

4d pharma says Merck KGaA and Pfizer cancer collaboration is 'big step forward'

4D pharma PLC's (LON:DDDD) chief executive Duncan Peyton talks to Proactive London's Katie Pilbeam about the clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc.

Peyton says 'it's another step forward in how we work and expand our oncology franchise' which will begin with a clinical trial this year with BAVENCIO. 

This is a drug for advanced or metastatic urothelial carcinoma (a form of bladder cancer) developed by Merck and Pfizer, in combination with UK group’s MRx0518.

Quick facts: 4D pharma PLC

Price: 123.0755 GBX

Market: LSE
Market Cap: £1.63 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...


Market Report: FTSE kicks off the week in positive territory as oil prices rise

FTSE 100 made a bright start on hopes for vaccines and higher oil prices, though the more UK-focused FTSE250 went the other way on Brexit worries. London’s blue-chip index rose 16 to 6,505.   Tesco has called for a tax on online rivals such as Amazon. Ken Murphy, the supermarket’s...

3 weeks, 3 days ago

2 min read